Immune modulation in advanced radiotherapies: Targeting out-of-field effects

Cancer Letters

Volumn 368, Issue 2, 2015, Pages 246-251

  Hanna, Gerard G ^a   Coyle, Victoria M ^a   Prise, Kevin M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Abscopal effect; Immunotherapy; Radiotherapy; SABR; Stereotactic

Indexed keywords

CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELLULAR IMMUNITY; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IONIZING RADIATION; NONHUMAN; OUT OF FIELD EFFECT; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; SHORT SURVEY; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNE SYSTEM; IMMUNOLOGY; NEOPLASMS;

ANIMALS; HUMANS; IMMUNE SYSTEM; NEOPLASMS;

EID: 84941874961     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.04.007     Document Type: Review

References (104)

1. Verellen D., De Ridder M., Linthout N., et al. Innovations in image-guided radiotherapy. Nat. Rev. Cancer 2007, 7:949-960.
2. Jain P., Baker A., Distefano G., et al. Stereotactic ablative radiotherapy in the UK: current status and developments. Br. J. Radiol 2013, 86:20130331.
3. Lagerwaard F.J., Verstegen N.E., Haasbeek C.J., et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys 2012, 83:348-353.
4. Onishi H., Shirato H., Nagata Y., et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?. Int. J. Radiat. Oncol. Biol. Phys 2011, 81:1352-1358.
5. Tree A.C., Khoo V.S., Eeles R.A., et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013, 14:e28-e37.
6. Palma D., Lagerwaard F., Rodrigues G., et al. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int. J. Radiat. Oncol. Biol. Phys 2012, 82:1149-1156.
7. Brown J.M., Carlson D.J., Brenner D.J. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?. Int. J. Radiat. Oncol. Biol. Phys 2014, 88:254-262.
8. Diot Q., Kavanagh B., Schefter T., et al. Regional normal lung tissue density changes in patients treated with stereotactic body radiation therapy for lung tumors. Int. J. Radiat. Oncol. Biol. Phys 2012, 84:1024-1030.
9. Drake C.G., Jaffee E., Pardoll D.M. Mechanisms of immune evasion by tumors. Adv. Immunol 2006, 90:51-81.
10. Finn O.J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol 2012, 23(Suppl. 8):viii6-viii9.
11. Postow M.A., Callahan M.K., Wolchok J.D. The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?. Clin. Cancer Res 2012, 18:1821-1823.
12. Prise K.M., O'Sullivan J.M. Radiation-induced bystander signalling in cancer therapy. Nat. Rev. Cancer 2009, 9:351-360.
13. Hatzi V.I., Laskaratou D.A., Mavragani I.V., et al. Non-targeted radiation effects in vivo: a critical glance of the future in radiobiology. Cancer Lett 2015, 356(1):34-42.
14. Postow M.A., Callahan M.K., Barker C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med 2012, 366:925-931.
15. Golden E.B., Demaria S., Schiff P.B., et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunology Research 2013, 1:365-372.
16. Zeng J., See A.P., Phallen J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys 2013, 86:343-349.
17. Deng L., Liang H., Burnette B., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest 2014, 124:687-695.
18. Mole R.H. Whole body irradiation; radiobiology or medicine?. Br. J. Radiol 1953, 26:234-241.
19. Golden E.B., Frances D., Pellicciotta I., et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. OncoImmunology 2014, 3:e28518.
20. Schaue D., Micewicz E.D., Ratikan J.A., Xie M.W., Cheng G., McBride W.H. Radiation and inflammation. Semin. Radiat. Oncol 2015, 25(1):4-10.
21. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34(5):637-650.
22. Ashworth A., Rodrigues G., Boldt G., Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 2013, 82(2):197-203.
23. Hellman S., Weichselbaum R.R. Oligometastases. J. Clin. Oncol 1995, 13:8-10.
24. Macdermed D.M., Weichselbaum R.R., Salama J.K. A rationale for the targeted treatment of oligometastases with radiotherapy. J. Surg. Oncol 2008, 98:202-206.
25. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol 2011, 29:235-271.
26. Reuschenbach M., von Knebel Doeberitz M., Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol. Immunother 2009, 58:1535-1544.
27. Godet Y., Fabre E., Dosset M., et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin. Cancer Res 2012, 18:2943-2953.
28. Mlecnik B., Bindea G., Pages F., Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 2011, 30:5-12.
29. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
30. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
31. Kerkar S.P., Restifo N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012, 72:3125-3130.
32. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
33. Hudis C.A. Trastuzumab - mechanism of action and use in clinical practice. NEJM 2007, 357:39-51.
34. Davar D., Tarhini A.A., Kirkwood J.M. Adjuvant therapy for melanoma. Cancer J. 2012, 18:192-202.
35. Amin A., White R.L. High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?. Oncology (Williston Park) 2013, 27:680-691.
36. Mocellin S., Lens M.B., Pasquali S., et al. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst. Rev 2013, 6:Cd008955.
37. Benson D.M., Hofmeister C.C., Padmanabhan S., et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012, 120:4324-4333.
38. Prendergast G.C., Smith C., Thomas S., et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol. Immunother 2014, 63:721-735.
39. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. NEJM 2010, 363:411-422.
40. Kruit W.H., Suciu S., Dreno B., et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J. Clin. Oncol 2013, 31:2413-2420.
41. Vazquez A.M., Hernandez A.M., Macias A., et al. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front. Oncol 2012, 2:150.
42. Rossi G.R., Mautino M.R., Awwad D.Z., et al. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity. J. Immunother 2008, 31:545-554.
43. Kohrt H.E., Colevas A.D., Houot R., et al. Targeting CD137 enhances the efficacy of cetuximab. J. Clin. Invest 2014, 124:2668-2682.
44. Shi X., Dornan D. To respond or not to respond to CD40 agonism: that is the prediction. Oncoimmunology 2012, 1:83-85.
45. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEJM 2010, 363:711-723.
46. Woo S.R., Turnis M.E., Goldberg M.V., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72:917-927.
47. Weinberg A.D., Morris N.P., Kovacsovics-Bankowski M., et al. Science gone translational: the OX40 agonist story. Immunol. Rev 2011, 244:218-231.
48. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med 2012, 366:2443-2454.
49. Brahmer J.R., Tykodi S.S., Chow L.Q.M., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. NEJM 2012, 366:2455-2465.
50. Robert C., Ribas A., Wolchok J.D., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
51. Robert C., Long G.V., Brady B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med 2014, 372:320-330.
52. Pol J., Bloy N., Obrist F., et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2014, 3:e28694.
53. Tarhini A.A., Gogas H., Kirkwood J.M. IFN-alpha in the treatment of melanoma. J. Immunol 2012, 189:3789-3793.
54. Mellstedt H., Vansteenkiste J., Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011, 73:11-17.
55. Vansteenkiste J., Zielinski M., Linder A., et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J. Clin. Oncol 2013, 31:2396-2403.
56. ESMO FDA backs continued study of belagenpumatucel-L for subgroups of patients based on data from phase III STOP trial. ESMO 2003, http://www.esmo.org/Conferences/Past-Conferences/European-Cancer-Congress-2013/News/Belagenpumatucel-L-Therapeutic-Tumour-Cell-Vaccine-for-Non-Small-Cell-Lung-Cancer.
57. Eggermont A.M. Immunotherapy: vaccine trials in melanoma - time for reflection. Nat. Rev. Clin. Oncol 2009, 6:256-258.
58. Gajewski T.F., Schreiber H., Fu Y.-X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol 2013, 14:1014-1022.
59. Spranger S., Spaapen R.M., Zha Y., et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013, 5:200ra116.
60. Collins A.V., Brodie D.W., Gilbert R.J.C., et al. The interaction properties of costimulatory molecules revisited. Immunity 2002, 17:201-210.
61. Chen W., Jin W., Wahl S.M. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J. Exp. Med 1998, 188:1849-1857.
62. Wang J., Yoshida T., Nakaki F., et al. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11823-11828.
63. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol 2012, 24:207-212.
64. Zhang Y., Wang L., Li Y., et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. OncoTargets Ther 2014, 7:567-573.
65. Momtaz P., Postow M.A. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers. Med 2014, 7:357-365.
66. Herbst R.S., Soria J.C., Kowanetz M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
67. Berger R., Rotem-Yehudar R., Slama G., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res 2008, 14:3044-3051.
68. Siva S., Callahan J., MacManus M.P., et al. Abscopal [corrected] effects after conventional and stereotactic lung irradiation of non-small-cell lung cancer. J. Thorac. Oncol 2013, 8:e71-e72.
69. Antoniades J., Brady L.W., Lightfoot D.A. Lymphangiographic demonstration of the abscopal effect in patients with malignant lymphomas. Int. J. Radiat. Oncol. Biol. Phys 1977, 2:141-147.
70. Ohba K., Omagari K., Nakamura T., et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 1998, 43:575-577.
71. Ehlers G., Fridman M. Abscopal effect of radiation in papillary adenocarcinoma. Br. J. Radiol 1973, 46:220-222.
72. Stamell E.F., Wolchok J.D., Gnjatic S., et al. The abscopal effect associated with a systemic anti-melanoma immune response. Int. J. Radiat. Oncol. Biol. Phys 2013, 85:293-295.
73. Demaria S., Ng B., Devitt M.L., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys 2004, 58:862-870.
74. Formenti S.C., Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009, 10:718-726.
75. Prise K.M., Schettino G., Folkard M., Held K.D. New insights on cell death from radiation exposure. Lancet Oncol 2005, 6:520-528.
76. Eriksson D., Stigbrand T. Radiation-induced cell death mechanisms. Tumor Biol 2010, 31:363-372.
77. Blyth B.J., Sykes P.J. Radiation-induced bystander effects: what are they, and how relevant are they to human radiation exposures?. Radiat. Res 2011, 176:139-157.
78. Butterworth K.T., McGarry C.K., Trainor C., et al. Out-of-field cell survival following exposure to intensity-modulated radiation fields. Int. J. Radiat. Oncol. Biol. Phys 2011, 79:1516-1522.
79. McMahon S.J., McGarry C.K., Butterworth K.T., et al. Implications of intercellular signaling for radiation therapy: a theoretical dose-planning study. Int. J. Radiat. Oncol. Biol. Phys 2013, 87:1148-1154.
80. Demaria S., Formenti S.C. Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int. J. Radiat. Biol 2007, 83:819-825.
81. Rodel F., Frey B., Multhoff G., Gaipl U. Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett 2015, 356:105-113.
82. Lugade A.A., Sorensen E.W., Gerber S.A., et al. Radiation-induced IFN-γ production within the tumor microenvironment influences antitumor immunity. J. Immunol 2008, 180:3132-3139.
83. Lugade A.A., Moran J.P., Gerber S.A., et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol 2005, 174:7516-7523.
84. Matsumura S., Demaria S. Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat. Res 2010, 173:418-425.
85. Kwilas A.R., Donahue R.N., Bernstein M.B., Hodge J.W. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front. Oncol 2012, 2:104.
86. Makinde A.Y., John-Aryankalayil M., Palayoor S.T., et al. Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy. Mol. Cancer Res 2013, 11:5-12.
87. Friedman E.J. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr. Pharm. Des 2002, 8:1765-1780.
88. Janssens S., Tschopp J. Signals from within: the DNA-damage-induced NF-[kappa]B response. Cell Death Differ 2006, 13:773-784.
89. Ifeadi V., Garnett-Benson C. Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. PLoS ONE 2012, 7:e31762.
90. Formenti S.C., Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl. Cancer Inst 2013, 105:256-265.
91. Chi K.-H., Liu S.-J., Li C.-P., et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J. Immunother 2005, 28:129-135.
92. Shibamoto Y., Okamoto M., Kobayashi M., et al. Immune-maximizing (IMAX) therapy for cancer: combination of dendritic cell vaccine and intensity-modulated radiation. Mol. Clin. Oncol 2013, 1:649-654.
93. Gulley J.L., Arlen P.M., Bastian A., et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res 2005, 11:3353-3362.
94. Lechleider R.J., Arlen P.M., Tsang K.Y., et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin. Cancer Res 2008, 14:5284-5291.
95. Iinuma H., Fukushima R., Inaba T., et al. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J. Transl. Med 2014, 12:84.
96. ClinicalTrials.Gov, Pancreatic Tumor Cell Vaccine (GVAX) Low dose cyclophosphamide, fractionated stereotactic body radiation therapy (SBRT), and FOLFIRINOX chemotherapy in patients with resected adenocarcinoma of the pancreas Available at:, accessed 02.04.15. https://clinicaltrials.gov/ct2/show/NCT01595321.
97. Chamoto K., Takeshima T., Wakita D., et al. Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells. Cancer Sci 2009, 100:934-939.
98. Sebastian M., Papachristofilou A., Weiss C., et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 2014, 14:748.
99. Crittenden M., Kohrt H., Levy R., et al. Current clinical trials testing combinations of immunotherapy and radiation. Semin. Radiat. Oncol 2015, 25(1):54-64.
100. ClinicalTrials.Gov AMP-224, a PD-1 inhibitor, in Combination with Stereotactic Body Radiation Therapy in People with Metastatic Colorectal Cancer accessed 02.04.15. https://clinicaltrials.gov/ct2/show/NCT02298946?term=%22PD-1%22+AND+%22Radiotherapy%22%26rank=1.
101. ClinicalTrials.Gov MPDL3280A and stereotactic ablative radiotherapy in patients with non-small cell lung cancer accessed 02.04.15. https://clinicaltrials.gov/ct2/show/NCT02400814?term=%22PD-1%22+AND+%22Radiotherapy%22%26rank=8.
102. Klug F., Prakash H., Huber P.E., et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013, 24:589-602.
103. Dewan M.Z., Galloway A.E., Kawashima N., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res 2009, 15:5379-5388.
104. Durante M., Reppingen N., Held K.D. Immunologically augmented cancer treatment using modern radiotherapy. Trends Mol. Med 2013, 19:565-582.